U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Infiltrating bladder urothelial carcinoma

MedGen UID:
233582
•Concept ID:
C1334281
•
Neoplastic Process
Synonyms: Infiltrating Bladder Urothelial Carcinoma; infiltrating bladder urothelial carcinoma; Infiltrating Transitional Cell Carcinoma of the Urinary Bladder; infiltrating transitional cell carcinoma of the urinary bladder; Invasive Bladder Transitional Cell Carcinoma; invasive bladder transitional cell carcinoma; Invasive Bladder Urothelial Carcinoma; invasive bladder urothelial carcinoma; Invasive Transitional Cell Carcinoma of the Urinary Bladder; invasive transitional cell carcinoma of the urinary bladder
 
Monarch Initiative: MONDO:0003890

Definition

An invasive urothelial carcinoma that arises from the urinary bladder urothelium. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVInfiltrating bladder urothelial carcinoma

Professional guidelines

PubMed

APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L
Neurol Res 2024 Mar;46(3):227-242. Epub 2024 Jan 22 doi: 10.1080/01616412.2023.2287340. PMID: 38007705
Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
Rangel MMM, Linhares LCM, de Oliveira KD, Suzuki DOH, Maglietti FH, de Nardi AB
Sci Rep 2023 Nov 29;13(1):21078. doi: 10.1038/s41598-023-45433-4. PMID: 38030630Free PMC Article
Stage T1 bladder cancer: diagnostic criteria and pitfalls.
Lopez-Beltran A, Cheng L
Pathology 2021 Jan;53(1):67-85. Epub 2020 Nov 3 doi: 10.1016/j.pathol.2020.09.014. PMID: 33153725

Recent clinical studies

Etiology

Young population bladder neoplasms.
Çivi Çetin K, Öner S, Erdoğan B, Simşek G, Sezer M
Eur Rev Med Pharmacol Sci 2023 Nov;27(21):10454-10461. doi: 10.26355/eurrev_202311_34320. PMID: 37975369
Receptor Tyrosine Kinase Pathway and Infiltrating Urothelial Carcinoma.
Buyucek S, Coskun SK, Onal B, Gamsizkan M, Cangur S, Esbah O
J Environ Pathol Toxicol Oncol 2023;42(1):65-77. doi: 10.1615/JEnvironPatholToxicolOncol.2022044380. PMID: 36734953
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X, Wang Y, A G, Qu C, Chen J
Front Immunol 2021;12:721030. Epub 2021 Aug 31 doi: 10.3389/fimmu.2021.721030. PMID: 34531868Free PMC Article
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article
Stage T1 bladder cancer: diagnostic criteria and pitfalls.
Lopez-Beltran A, Cheng L
Pathology 2021 Jan;53(1):67-85. Epub 2020 Nov 3 doi: 10.1016/j.pathol.2020.09.014. PMID: 33153725

Diagnosis

Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W, Liu Z, Liu T
Cell Signal 2024 May;117:111107. Epub 2024 Feb 16 doi: 10.1016/j.cellsig.2024.111107. PMID: 38369265
Molecular profile of bladder cancer progression to clinically aggressive subtypes.
Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, McConkey DJ, Wei P, Czerniak B
Nat Rev Urol 2024 Jul;21(7):391-405. Epub 2024 Feb 6 doi: 10.1038/s41585-023-00847-7. PMID: 38321289
Molecular classification of urothelial bladder carcinoma.
Schwarzova L, Varchulova Novakova Z, Danisovic L, Ziaran S
Mol Biol Rep 2023 Sep;50(9):7867-7877. Epub 2023 Jul 31 doi: 10.1007/s11033-023-08689-7. PMID: 37525073Free PMC Article
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article

Therapy

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
Song Y, Peng Y, Qin C, Wang Y, Yang W, Du Y, Xu T
J Immunother Cancer 2023 Sep;11(9) doi: 10.1136/jitc-2022-006643. PMID: 37777251Free PMC Article
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X, Wang Y, A G, Qu C, Chen J
Front Immunol 2021;12:721030. Epub 2021 Aug 31 doi: 10.3389/fimmu.2021.721030. PMID: 34531868Free PMC Article
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article
Immunotherapy for genitourinary tumors.
Nakayama T, Kitano S
Int J Urol 2019 Mar;26(3):326-333. Epub 2019 Feb 1 doi: 10.1111/iju.13902. PMID: 30710374

Prognosis

Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Liu B, Fu X, Du Y, Feng Z, Chen R, Liu X, Yu F, Zhou G, Ba Y
Carcinogenesis 2023 Aug 18;44(6):525-534. doi: 10.1093/carcin/bgad043. PMID: 37335542
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer.
Wang Y, Zhang Y, Wang F, Li T, Song X, Shi H, Du J, Zhang H, Jing H, Han J, Tong D, Zhang J
Sci Rep 2022 Nov 2;12(1):18518. doi: 10.1038/s41598-022-21328-8. PMID: 36323715Free PMC Article
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article

Clinical prediction guides

Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
Yang W, Liu Z, Liu T
Cell Signal 2024 May;117:111107. Epub 2024 Feb 16 doi: 10.1016/j.cellsig.2024.111107. PMID: 38369265
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X, Wang Y, A G, Qu C, Chen J
Front Immunol 2021;12:721030. Epub 2021 Aug 31 doi: 10.3389/fimmu.2021.721030. PMID: 34531868Free PMC Article
A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors.
Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y, Su C, Zhang W, Sun X, He J, Gao X, Yang J
Genomics 2020 Nov;112(6):3958-3967. Epub 2020 Jul 6 doi: 10.1016/j.ygeno.2020.06.044. PMID: 32645525

Recent systematic reviews

Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Kardoust Parizi M, Matsukawa A, Bekku K, Klemm J, Alimohammadi A, Laukhtina E, Karakiewicz P, Chiujdea S, Abufaraj M, Krauter J, Shariat SF
Eur Urol Oncol 2024 Aug;7(4):663-676. Epub 2023 Nov 18 doi: 10.1016/j.euo.2023.11.001. PMID: 37980251
French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
Neuzillet Y, Pradère B, Xylinas E, Allory Y, Audenet F, Loriot Y, Masson-Lecomte A, Roumiguié M, Seisen T, Traxer O, Leon P, Roupret M
Prog Urol 2022 Nov;32(15):1102-1140. doi: 10.1016/j.purol.2022.08.006. PMID: 36400479
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlangh R, Katayama S, Grossmann NC, Moschini M, Enikeev D, Shariat SF; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
Urol Oncol 2021 Mar;39(3):180-190. Epub 2021 Jan 8 doi: 10.1016/j.urolonc.2020.12.019. PMID: 33423937
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, Shariat SF
World J Urol 2020 Jun;38(6):1437-1449. Epub 2019 Sep 6 doi: 10.1007/s00345-019-02936-y. PMID: 31493109Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On
    • Infiltrating bladder urothelial carcinoma
      Infiltrating bladder urothelial carcinoma
      MedGen
    • RNA Folding
      RNA Folding
      The processes of RNA tertiary structure formation.<br/>Year introduced: 2012
      MeSH
    • Egtazic Acid
      Egtazic Acid
      A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.<br/>Year introduced: 1992
      MeSH
    • Ethambutol
      Ethambutol
      An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteri...<br/>Year introduced: 1968(1963)
      MeSH

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...